XueMing Xin

Executive Director, Lung Cancer Marketing @ AstraZeneca

About

With a dynamic 20-year career encompassing sales, marketing, patient solutions, and diagnostics in the oncology field.

Country

China

City

Shanghai

Industry

Pharmaceuticals

Skill

战术计划, 中文, 跨团队协作, 组合管理, 预测, 团队领导力, Oncology, Urology, Patient Education, Cancer, 策略, 药剂学, 癌症, 生物技术, 制药业, 肿瘤学, 产品发布, Breast Cancer, Hospitals, Pharmaceutical Industry

Experience

Executive Director, Lung Cancer Marketing

AstraZeneca

2025-7 - Present · 1 yr 3 mos

Shanghai, China

Executive Director , Marketing Excellence & Patient Service Center

AstraZeneca

2024-6 - 2025-7 · 1 yr 2 mos

Shanghai, China

Led Marketing Excellence, Launch Excellence, and Event Excellence transformation across AZ BU and portfolio · Built and deployed next generation launch excellence framework improving speed and consistency · Established foundational Patient Service Program (PSP) operating model and adherence framework · Improved enterprise-wide execution discipline organizational capability building across China BUs

Patient Solution & Diagnosis Director

Pfizer

2022-3 - 2024-6 · 2 yrs 4 mos

中国上海市

✓ Led and mentored a diverse team of healthcare professionals, ensuring alignment with project goals and achieving exceptional patient-centric outcomes. ✓ Oversaw the strategic management of a nurse team of over 50, leveraging third-party expertise to optimize operational efficiency and ensure high-quality patient care. ✓ Successfully implemented the Patient Solutions Model, recognized with the SHANGHAI DESIGN 100+ award for the innovative ‘One Stop Patient Services Solution’.

Marketing Director / TA Lead – Breast Cancer Franchise (Progressive Roles)

Pfizer

2018-10 - 2022-2 · 3 yrs 5 mos

上海

Built multi-asset oncology franchise leadership primarily in Breast Cancer, spanning oral and injectable therapies across full lifecycle stages, from Innovative brands to VBP brands. · Owned ~$250M breast cancer franchise portfolio including Ibrance and legacy brands · Drove Aromasin to exceed $100M revenue milestone, contributing significant franchise growth · Partnered with national stakeholders to build disease-level quality control ecosystem, enhancing standardized breast cancer treatment pathway

Launch Lead - CDK4/6

Pfizer

2017-12 - 2018-9 · 10 mos

上海静安区

✓Orchestrated the formation of the cross-functional launch team as CDK4/6 China Launch Lead, achieving a China launch three years ahead of the original plan. ✓Established a patient-centric support system and introduced an innovative pay-for-performance insurance program as Brand Lead at CDK4/6, resulting in the successful launch of the world's first performance-based insurance project.

Marketing Lead, GU/GI Oncology Franchise (Progressive Roles)

Pfizer

2011-1 - 2017-12 · 7 yrs

Shanghai

Built from single-product leadership to multi-asset oncology franchise responsibility across GI/GU · Expanded from single indication (RCC) to multi-asset GI/GU oncology portfolio ownership, covering Sutent and Inlyta · Led franchise-level strategy development, portfolio prioritization, and lifecycle management, strengthening leadership in RCC and broader GI/GU oncology markets · Delivered record-speed launch (86 days) for Inlyta, setting benchmark for oncology launches in China · Achieved #1 market position in RCC, reinforcing category leadership under competitive pressure · Played key role in market access strategy and NRDL inclusion, navigating complex policy environment · Built strong KOL network and treatment ecosystem, supporting sustained franchise growth